Sign in
CompletedNo phase

Effect of Extended Cannabis Abstinence on PTSD Symptoms

Key facts

Who runs it
Centre for Addiction and Mental Health
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
24 people enrolled
Started
2 Feb 2022
Ended
1 Sept 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Contingency-management
  • Enhanced usual care
Record updated
23 October 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Subjects aged between 18 and 55 years (from both sexes [or genders])
  • Diagnosed with CUD (moderate or severe) according to the Structured Clinical Interview for DSM-IV (SCID) (mode of cannabis consumption can be inhalation or ingestion)
  • Diagnosis of current (past 30 days) PTSD, using the CAPS-5 on screening
  • On antidepressant medication(s) for at least 1 month (to ensure safety and homogeneity as PTSD treatment of our population)
  • Be able to provide written informed consent; and
  • Be able to communicate in English

Who cannot take part

  • diagnosed with a severe or unstable medical illness that precludes safe participation in the study as per the study physician
  • diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder or current acute psychosis or mania based on DSM-5 criteria
  • current suicidality risk as indicated by the Columbia Suicide Severity Rating Scale (C-SSRS) with concurrence after the study physician's evaluation if the response to C-SSRS questions 1 or 2 is "yes" 34; and
  • have pain interfering with normal function as reported by the 12-Item Short Form Survey (SF-12) (moderate or higher interference)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This will be a 12-week randomized trial. Outpatients and patients from the Mood and Anxiety program at the Centre for Addiction and Mental Health (CAMH) with a current diagnosis of post-traumatic stressed disorder (PTSD) and cannabis-use disorder (CUD) will be randomized to receive individual motivational interviewing therapy and contingency management (n = 12) or individual motivational interviewing therapy alone (control group, n = 12) after enrolment.

The 2 groups in the trial

  • Contingency management groupExisting treatment, for comparison

    Randomized to receive individual motivational interviewing therapy and contingency management

    Treatment: Contingency-management and Enhanced usual care

  • Control groupOther group

    Randomized to receive individual motivational interviewing therapy alone

    Treatment: Enhanced usual care

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Publications
Record updated
23 October 2026